Mental health studies with practical context.

Researchers are studying SEP-363856, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.

Researchers are comparing EB-1020 (Centanafadine) 164.4 mg and EB-1020 (Centanafadine) 328.8 mg, tracking side effects to assess long-term safety in adults with ADHD.

A Phase 3, Multicenter, Open-label, Uncontrolled, Long-term Japan-China Joint Trial to Evaluate the Safety and Efficacy of EB-1020 QD XR Capsules Administered Orally Once Daily in Children and Adolescents With Attention- Deficit/Hyperactivity Disorder

Researchers compare brenipatide with placebo, both added to usual treatment, to find out whether it delays a new mood episode in adults with bipolarity. They monitor changes in symptoms and the safety of the added medicine.

This study evaluates the safety and effectiveness of Brenipatide for people with depression.

This study evaluates the safety and effectiveness of Brenipatide for people with schizophrenia.

A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2)

A Randomized, Double-blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once-Daily Oral Administration of Vortioxetine in Japanese Pediatric Patients 12 to 17 Years of Age With Major Depressive Disorder (MDD)

This extension study evaluates the long-term safety and tolerability of KarXT for mania or mania with mixed features in people living with bipolarity type I.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease

Researchers compare KarXT with placebo, each added to lithium, valproate or lamotrigine, in people with bipolarity type I experiencing mania, with or without mixed features. They want to know whether adding KarXT improves manic symptoms and assess its safety.

Researchers compare KarXT with placebo to find out whether it reduces manic symptoms in people with bipolarity type I. They also assess side effects and safety during treatment.